hotspot -WSS

hotspot

author：explore 2025-10-01 11:01:51 - browse：66189

Daniel M. Skovronsky on stage at the 2023 STAT Summit. — Dan Skovronsky, Eli Lilly's chief scientific officer, at the 2023 STAT Summit. STAT

PHILADELPHIA — In a sense, the annual meeting of the American Heart Association wasn’t a huge one for Eli Lilly. Its biggest news was about a very early study of a drug to lower blood levels of Lp(a), a protein related to cholesterol that is mainly being watched by lipidologists and drug company analysts.

But in another way, the future of Lilly, now the biggest drug company by market capitalization, hung in the balance. Why? Because researchers were presenting data on the ability of Novo Nordisk’s obesity drug Wegovy to prevent heart attacks, strokes, and deaths in people with overweight who have established cardiovascular disease. That has big implications for the market for Lilly’s own obesity drug, Zepbound, which was approved by the Food and Drug Administration last week, and for the company’s future efforts in obesity.

STAT sat down with Lilly’s chief scientific officer, Dan Skovronsky, at the AHA meeting to talk about the obesity drugs known as GLP-1s, the new Lp(a) drug, and the company’s partnership with the gene editing firm Verve. An edited transcript of the conversation follows.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： At least 13 dead in Texas as scorching temps continue
Next article： First medicine developed to treat MASH expected to be approved soon

WSS

Change Healthcare payments predicted restored March 15

FDA approves potent Eli Lilly obesity drug, Zepbound

In surprise move, FDA calls for advisory committee on Lilly's Alzheimer's drug

Victims of gun violence feel impacts long after bullet wound

AstraZeneca CEO says participant had neurological symptoms, could be discharged today

NEJM study link tiny plastics in blood vessels to heart problems

knowledge

hotspot

focus

Anesthesiologist group: stop taking Ozempic before surgery

Readout Newsletter: Acadia, Eli Lilly, Madrigal Pharma updates

Sports medicine is finally prioritizing gender equality

White House calls on federal agencies to crack down on AI abuses

ChatGPT in medicine: STAT answers readers' burning questions

Former medical device CEO who sold dummy, plastic parts convicted of fraud

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

In his State of the Union, Biden takes clear aim at 'Big Pharma'

Medicare details structure of new drug price negotiation program

First medicine developed to treat MASH expected to be approved soon

focus

Readout LOUD podcast: Venture capital turmoil, obesity drug competition

UnitedHealth quietly bought dozens of outpatient centers

Victims of gun violence feel impacts long after bullet wound

Change Healthcare cyberattack prompts Medicare loan program

Novo Nordisk obesity pill bests Wegovy in early trial

AstraZeneca CEO says participant had neurological symptoms, could be discharged today

entertainment

focus

hotspot

knowledge